The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 13, 2022

Filed:

May. 13, 2021
Applicant:

Biora Therapeutics, Inc., San Diego, CA (US);

Inventors:

Jeffrey A. Shimizu, Poway, CA (US);

Mitchell Lawrence Jones, La Jolla, CA (US);

Mark Sasha Drlik, Victoria, CA;

Iman Niknia, Victoria, CA;

Nathan John Muller, Victoria, CA;

Tuyen Nguyen, Victoria, CA;

Christopher Loren Wahl, San Diego, CA (US);

Edward Mudge, Cambridgeshire, GB;

Nicholas Mark Salt, Cambridgeshire, GB;

Nia Eleri Stevens, Cambridgeshire, GB;

Stuart Robert Abercrombie, Cambridgeshire, GB;

Christopher Ian Bunce, Cambridgeshire, GB;

Nelson Quintana, Temecula, CA (US);

Assignee:

Biora Therapeutics, Inc., San Diego, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61M 31/00 (2006.01);
U.S. Cl.
CPC ...
A61M 31/002 (2013.01); A61M 2210/106 (2013.01); A61M 2210/1042 (2013.01); A61M 2210/1064 (2013.01);
Abstract

A method of treating a disease or condition in a subject in need thereof is disclosed. The method comprising: trans-epithelially administering a dispensable substance to the gastrointestinal (GI) tract of the subject by orally administering an ingestible device comprising the dispensable substance to the subject. The ingestible device is configured for trans-epithelial delivery of the dispensable substance to the GI tract of the subject and the dispensable substance comprises a pharmaceutical formulation comprising a therapeutically effective amount of a glucagon receptor agonist or a glucagon-like peptide-1 (GLP-1) receptor agonist. The ingestible device releases the dispensable substance as at least one jet to a desired location of the GI tract of the subject.


Find Patent Forward Citations

Loading…